Long-term outcome in people who use drugs successfully treated for hepatitis C infection with glecaprevir/pibrentasvir
Background: Several clinical trials, including the recently published the GRAND PLAN study from Vancouver Infectious Diseases Center (VIDC), have demonstrated the efficacy of hepatitis C (HCV) therapy among active drug users, including those facing significant addiction-related and social challenges...
Saved in:
Main Authors: | Shana Yi, David Truong, Brian Conway |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-12-01
|
Series: | Journal of Virus Eradication |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2055664024000311 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Aleksandra Berkan-Kawińska, et al.
Published: (2024-07-01) -
Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis
by: Liwei Zhuang, et al.
Published: (2025-02-01) -
Patients with Chronic Hepatitis C - Who Should Not Be Treated?
by: Andreas Schüler, et al.
Published: (2000-01-01) -
Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study.
by: Hannah N Manley, et al.
Published: (2025-01-01) -
Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study
by: Hannah N. Manley, et al.
Published: (2025-01-01)